Navigation Links
Prolexys Pharmaceuticals Initiates Phase 1 Study
Date:8/29/2007

Novel Agent Administered in First-In-Human Study to Cancer Patients

SALT LAKE CITY, Aug. 29 /PRNewswire/ -- Prolexys Pharmaceuticals, Inc. today announced that its first-in-humans Phase 1 study of PRLX 93936 has begun. This open-label trial is designed to evaluate the safety, pharmacokinetic and pharmacodynamic properties of PRLX 93936 in patients with advanced solid tumors. Study sites include TGen Clinical Research at Scottsdale Healthcare in Scottsdale, Arizona, and Tower Cancer Research Foundation in Beverly Hills, California. The first Phase 1 study will be a dose-escalating trial involving up to 36 patients.

"We are enthusiastic about our participation in the study of this interesting new agent with what appears to be a unique mechanism of action," said Dr. Daniel Von Hoff, Physician-in-Chief and Director of Clinical Research at TGen, and the principal investigator for the study at Scottsdale Healthcare. "Rarely have we seen pre-clinical anti-tumor effects that match those produced by PRLX 93936. We're very hopeful that this compound will have a therapeutic effect in patients with tumors that are non-responsive to existing therapeutic agents."

"The initiation of this Phase I clinical trial demonstrates our commitment to develop novel approaches to cancer therapies based on the company's proteomics technology platform," said David Clark, President and CEO of Prolexys.

"Based on the broad anti-cancer activity we have seen in pre-clinical models, we are looking forward to evaluating the potential anti-cancer activity in humans for this new drug candidate," stated Dr. Sudhir Sahasrabudhe, Prolexys' Chief Scientific Officer.

About PRLX 93936

PRLX 93936 is a structural analog of a compound called erastin, in-licensed by Prolexys from the MIT/ Whitehead Institute in January 2005. Erastin was identified as a potential anti-cancer therapeutic in a screen against cell lines engineered to differentially express several oncogene
'/>"/>

SOURCE Prolexys Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2008)...3 Wyeth Pharmaceuticals,...day that it has submitted a,marketing authorizati...ncy,(EMEA) for approval to market its investigati...V13) for infants and young children. Wyeth is see...ccal disease (PD) caused by the 13,serotypes incl...
(Date:12/2/2008)...ire-USNewswire/ -- Researchers using functional,M...e area of the brain,responsible for suppressing m...,stress-related psychiatric disorders. Results of ...eeting of the Radiological Society of North Americ...ssion and other stress-related disorders,traumat...
(Date:12/2/2008)...Newswire/ -- Horizon Therapeutics, Inc., a,privat...d that two pivotal,Phase 3 trials evaluating its ...met all primary endpoints. HZT-501, a novel, propr...ibuprofen and famotidine, demonstrated a,statisti...n-steroidal,anti-inflammatory drug (NSAID)-induce...
(Date:12/1/2008)...swire/ -- TargeGen has announced that an oral,pre...ter, US-based clinical,trial of TG101348 in myelo...at,the 2008 American Society of Hematology (ASH) ...e as follows:, Title: A Phase I... JAK2-Selective Inhibitor, in Pat...
Breaking Medicine Technology:Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 2Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 3Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 4Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 5Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Plexus Systems Inc and Aberdeen Group Co host March 27 Webinar on Manufacturing Efficiency 15096 1Plexus Systems Inc and Aberdeen Group Co host March 27 Webinar on Manufacturing Efficiency 15096 2Plexus Systems Inc and Aberdeen Group Co host March 27 Webinar on Manufacturing Efficiency 15096 3MRI Can Be Predictor of Post Treatment Prostate Cancer Spread 15095 1MRI Can Be Predictor of Post Treatment Prostate Cancer Spread 15095 2Mounting evidence shows red wine antioxidant kills cancer 2618 1Mounting evidence shows red wine antioxidant kills cancer 2618 2Mounting evidence shows red wine antioxidant kills cancer 2618 3New York City Staffing Company Charged With Violating H 1B Program Following U S Labor Department Finding Almost 243 Million in Back Wages Due 156 W 15090 1New York City Staffing Company Charged With Violating H 1B Program Following U S Labor Department Finding Almost 243 Million in Back Wages Due 156 W 15090 2
...ne Plus Minocycline Showed Substantial,Reduction o...ng-Remitting Multiple Sclerosis , Combination Trea...s and Was Well Tolerated , KANSAS CITY, Mo, May 4,...tudy showed that a combination of Copaxone,(glatir...otic,minocycline reduced T1 Gadolinium (Gd)-enhanc...
...th May 2007 - CeNeS Pharmaceuticals plc,(LSE: CEN)...otes,the publication of an independent study in th...hase II NMDA antagonist, CNS 5161. CeNeS,is develo...thic,pain. The independent study builds on the wor... , In the study reported in ,Synapse, Dr Anat Bie...
Other Medicine Technology:Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 6Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 7Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 8Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 9Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 10Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 11Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 12Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 2Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 3
(Date:12/4/2008)...TIST HEALTH, a six-hospital,system based in Littl...m, has,expanded its use of Clinical Xpert(TM) Car...abled the system,s pharmacists to increase necessa...illion. , "Data we collected for the 220-be...ompts approximately half of the pharmacy clinical ...
(Date:12/4/2008)...study of 491 women with invasive ovarian cancer fo...r genetic testing of BRCA1 and BRCA2, the breast c...formed of their cancer risk. , Dr. Kelly Metcal...ronto,s Lawrence S. Bloomberg Faculty of Nursing, ...ch Institute, led the nursing study, which was pub...
(Date:12/4/2008)... on the eve of its 35th Anniversary, Ronald McDona...d Season of Giving marketing campaign to remind co...itiative, designed to drive personal donations, wi...ree core programs: Ronald McDonald House, Ronald M...obile. , OAK BROOK, III....
(Date:12/4/2008)...en Joffe, Craig Joffe, and,Alan Buckey today file...,Securities and Exchange Commission. The group p...4% of LCA-Vision, Inc. (Nasdaq: LCAV ), which,o...ction centers in 33 states,in the United States. ...CEO of,LCAV. Craig Joffe is the former Chief Ope...
Breaking Medicine News(10 mins):Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 2Health News:BAPTIST HEALTH Uses Real-Time Clinical Surveillance from Thomson Reuters to Lower Costs and Improve Quality in the Pharmacy 3Health News:Few Ontario women with invasive ovarian cancer referred for genetic testing of breast cancer genes 2Health News: Ronald McDonald House Charities Brings People Together Like Never Before with First-Ever, Multi-Channel Social Networking Campaign : Charity Finds New Ways to Encourage Seasonal Giving in Tough Economic Times 2Health News: Ronald McDonald House Charities Brings People Together Like Never Before with First-Ever, Multi-Channel Social Networking Campaign : Charity Finds New Ways to Encourage Seasonal Giving in Tough Economic Times 3Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 2Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 3Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 4Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 5Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 6
...l infections with an antibiotic gel reduced the pr...oughout the body,// pointing to further evidence o...ealth, investigators from the University at Buffal.... The investigators divided a sample of 100 adult...
...diation may cause skin cancer, but it also prevent... According to many, UV-B - the solar radiation tha..., and other skin cancers. That is generally true, ...that the reverse may also be the case - that UV-B ...
...icals Ltd today said its newly- found andti-diabet... trials by later this year. Mr Glenn Saldanha, Exe...wspersons that the company’s R&D team has establis... this molecule.// The global diabetes market is e...
...f bypass patients suffer mental decline after bypa...mbering. One leading theory is that the heart-lung...udy,// the loss of mental sharpness suffered by ma...gery may not be caused by the heart-lung machine u...
Other Medicine News:
Large solid mallet with patented Ortho-Grip® silicone rubber handle.
Angled ring curette.
Perisoteal rasp for elevating, dissecting, and scraping.
Stainless steel bone clamp.
Medicine Products: